ArticlePloS one2015
Serum interleukin (IL)-15 as a biomarker of Alzheimer's disease.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels.Communications biology · 2022Pooled it
- Meta-Analysis of the Association between Tea Intake and the Risk of Cognitive Disorders.PloS one · 2016Pooled it
- Dissecting Alzheimer's proteomic landscape through NULISA profiling of brain cell-specific extracellular vesicles.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The Muscle-Brain Axis in Aging: Mechanistic and Clinical Perspectives on Resistance Training and Cognitive Function.Biology · 2026Review
- Cytokine expression profile in the human brain of older adults.Journal of neuroinflammation · 2025Article
- Brain interleukins and Alzheimer's disease.Metabolic brain disease · 2025Review
- ZBP1 mediates the progression of Alzheimer's disease via pyroptosis by regulating IRF3.Molecular and cellular biochemistry · 2023Article
- Concordant and Discordant Cerebrospinal Fluid and Plasma Cytokine and Chemokine Responses in Mild Cognitive Impairment and Early-Stage Alzheimer's Disease.Biomedicines · 2023Article
- Age-dependent differences and similarities in the plasma proteomic signature of postoperative delirium.Scientific reports · 2023Article
- Muscle-Brain crosstalk in cognitive impairment.Frontiers in aging neuroscience · 2023Review
- Neuroimmune proteins can differentiate between tauopathies.Journal of neuroinflammation · 2022Article
- Graphene-Based Biosensors for Molecular Chronic Inflammatory Disease Biomarker Detection.Biosensors · 2022Review
- Inflammation in the CNS: Understanding Various Aspects of the Pathogenesis of Alzheimer's Disease.Current Alzheimer research · 2022Review
- Loss of APP in mice increases thigmotaxis and is associated with elevated brain expression of IL-13 and IP-10/CXCL10.Physiology & behavior · 2021Article
- Article
- Serum Adiponectin is Related to Dementia.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020Article
- The Contribution of Formyl Peptide Receptor Dysfunction to the Course of Neuroinflammation: A Potential Role in the Brain Pathology.Current neuropharmacology · 2020Review
- Blood-based protein predictors of dementia severity as measured by δ: Replication across biofluids and cohorts.Alzheimer's & dementia (Amsterdam, Netherlands) · 2019Article
- Article
- Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease.Acta neuropathologica communications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin (IL-15), a pro-inflammatory cytokine has been studied as a possible marker of Alzheimer's disease (AD); however its exact role in neuro-inflammation or the pathogenesis AD is not well understood yet. A Multiple Indicators Multiple Causes (MIMIC) approach was used to examine the relationship between serum IL-15 levels and AD in a well characterized AD cohort, the Texas Alzheimer's Research and Care Consortium (TARCC). Instead of categorical diagnoses, we used two latent construct d (for dementia) and g' (for cognitive impairments not contributing to functional impairments) in our analysis. The results showed that the serum IL-15 level has significant effects on cognition, exclusively mediated by latent construct d and g'. Contrasting directions of association lead us to speculate that IL-15's effects in AD are mediated through functional networks as d scores have been previously found to be specifically related to default mode network (DMN). Our finding warrants the need for further research to determine the changes in structural and functional networks corresponding to serum based biomarkers levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.